Oxatomide in the treatment of chronic urticaria. A double-blind placebo-controlled trial.

Abstract

Oxatomide was evaluated in a double-blind study of 35 patients with chronic urticaria. For 5 weeks patients received at random either 30 mg oxatomide b.i.d. or a placebo. Oxatomide significantly reduced not only the duration of the attacks but also the severity of erythema, lesions and itching. This lower level of suffering was clearly reflected by a diminished need for additional antiallergic medication. The overall response to treatment was rated excellent or good in 72% of the oxatomide-treated patients against only 23% of the controls which is a significant difference. Sleepiness was reported in 1 patient of each group.

• Authors: W Peremans, R L Mertens, J Morias, H Campaert
• Journal: Dermatologica (Dermatologica) Vol. 162 Issue 1 Pg. 42-50 ( 1981) ISSN: 0011-9075 [Print] Switzerland
• PMID: 7014277 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Piperazines
• Placebos
• oxatomide

Topics

• Adolescent
• Adult
• Chronic Disease
• Clinical Trials as Topic
• Double-Blind Method
• Female
• Humans
• Male
• Middle Aged
• Piperazines (therapeutic use)
• Placebos
• Urticaria (drug therapy)